Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks

BACKGROUND: Generic drugs may help to support antiretroviral treatment. We want to assess the efficacy and safety at 24 weeks of the change of coformulated (abacavir + lamivudine + dolutegravir) to (abacavir + lamivudine) coformulated as a generic pharmaceutical specialty + dolutegravir. METHODS: Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Olalla, Julián, Pérez-Stachowski, Javier, Tortajada, Begoña, Del Arco, Alfonso, Márquez, Efrén, De la Torre, Javier, Nieto, Miriam, García de Lomas, José María, Prada, José Luis, García-Alegría, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180504/
https://www.ncbi.nlm.nih.gov/pubmed/30305176
http://dx.doi.org/10.1186/s40360-018-0252-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180504/
https://www.ncbi.nlm.nih.gov/pubmed/30305176
http://dx.doi.org/10.1186/s40360-018-0252-z

Ejemplares similares